|
Match
|
Document |
Document Title |
|
|
US20140186950 |
SYNTHETIC MEMBRANE ANCHORS
Cells incorporating a synthetic molecule construct of the structure F—S1—S2-L where: F—S1 is an aminoalkylglycoside where F is a mono-, di-, tri- or oligo-saccharide and S1 is 2-aminoethyl,... |
|
|
US20110305777 |
DIMERIC IAP ANTAGONISTS
Smac mimetics that inhibit IAPs. |
|
|
US20150051267 |
BICISTRONIC GENE TRANSFER TOOLS FOR DELIVERY OF miRNAS AND PROTEIN CODING SEQUENCES
Compositions and methods relating to microRNA (miRNA) technology are disclosed. In particular, microRNA (miRNA) expression vectors and methods for the treatment of sensory disorders, e.g., for the... |
|
|
US20110263026 |
Construction of Protein-Responsive shRNA/RNAi Control System Using RNP Motif
An object of the present invention is to provide an RNAi control system using an RNA-protein interaction motif. The present invention provides an shRNA comprising: a guide strand having a sequence... |
|
|
US20100317590 |
REGULATION OF SKIN CHARACTERISTICS BY DICKKOPF1 (DKK1)
The present disclosure is generally related to methods of inducing non-palmoplantar skin to develop a palmoplantar phenotype, for example, methods for increasing skin thickness, decreasing skin... |
|
|
US20130202682 |
SYNTHETIC MATRIX VESICLES FOR BIOMIMETIC MINERALIZATION
Compositions of synthetic matrix vesicles with mineralization relevant ions which direct mineralization of a biomimetic mineral phase and methods for use thereof are provided. |
|
|
US20110142812 |
SUPPRESSIVE MACROPHAGES, C-REACTIVE PROTEIN AND THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS AND IMMUNE THROMBOCYTOPENIC PURPURA
The present invention relates to the use of suppressive macrophage or dendritic cells (activated with C-reactive protein or CRP-related compounds), for the treatment of various disease states and... |
|
|
US20110300172 |
FUSION PROTEINS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS FOR TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS
A fusion protein comprising an antigenic fragment of apoB-100 and a suitable carrier and related compositions methods and systems. |
|
|
US20120231997 |
RECOMBINANT HUMAN CC10 PROTEIN FOR TREATMENT OF INFLUENZA
Methods of using recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, to reduce virus titers in the tissues of patients, particularly influenza titers in lung tissues are... |
|
|
US20140314673 |
TREATMENT OF CANCER WITH DIHYDROPYRAZINO-PYRAZINES
Provided herein are methods for treating or preventing head and neck squamous cell carcinoma characterized by deletion of chromosome 11q22 or loss of ataxia telangiectasia mutated expression,... |
|
|
US20140243264 |
METHODS OF TREATMENT FOR RETINAL DISEASES
The present invention provides methods of treating a retinal disorder comprising administering an effective amount of a neurotrophic factor to a subject having the retinal disorder. The... |
|
|
US20150071906 |
DELIVERY SYSTEM FOR FUNCTIONAL NUCLEASES
Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided.... |
|
|
US20110318835 |
Implant Surface Treatment Method Having Tissues Integrated
The present disclosure uses different kinds of surface treatment processes on titanium-made dental implants. The growth and attachment conditions of bone cells (MC3T3-E), fibroblasts(NIH 3T3) and... |
|
|
US20110081369 |
IMMUNE MODULATION WITH DEATH RECEPTOR-INDUCED APOPTOSIS
This invention provides chimeric proteins comprising an apoptosis-inducing molecule fused to a member of a binding pair that is capable of binding to a selected cell that expresses a death... |
|
|
US20110207816 |
ALTERNATE MORPHEEINS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES
A composition having an agent adapted to affect a multimeric protein by binding to a binding site of the multimeric protein and thereby affecting an equilibrium of units, wherein the multimeric... |
|
|
US20140010885 |
SELF-ASSEMBLING NANOPARTICLE DRUG DELIVERY SYSTEM
A self-assembling nanoparticle drug delivery system for the delivery of various bioactive agents including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The... |
|
|
US20110223240 |
COMPOUNDS FOR REVERSING AND INHIBITING PROTEIN AGGREGATION, AND METHODS FOR MAKING AND USING THEM
The invention provides compositions for increasing the clearance of protein aggregates, and pharmaceutical compositions comprising them, and methods for making and using them, including methods... |
|
|
US20150071903 |
USE OF CATIONIC LIPIDS TO DELIVER CAS9
Compositions, methods, strategies, kits, and systems for the supercharged protein-mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro are provided.... |
|
|
US20140273217 |
PRODRUG ACTIVATION IN CANCER CELLS USING MOLECULAR SWITCHES
The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a... |
|
|
US20110135620 |
PRODRUG ACTIVATION IN CANCER CELLS USING MOLECULAR SWITCHES
The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a... |
|
|
US20140377235 |
METHODS FOR USING SYNTHETIC TRITERPENOIDS IN THE TREATMENT OF BONE OR CARTILAGE DISEASES OR CONDITIONS
The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions. |
|
|
US20130089526 |
Methods for Using Synthetic Triterpenoids in the Treatment of Bone or Cartilage Diseases or Conditions
The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions. |
|
|
US20150203477 |
COMPOUNDS AND METHODS FOR ACTIVATING THE APOPTOTIC ARM OF THE UNFOLDED PROTEIN RESPONSE
N-substituted sulfonylphenyl-5-nitrofuranyl-2-carboxamide derived compounds, which selectively activate the apoptotic, but not the adaptive arm, of the Unfolded Protein Response are provides as is... |
|
|
US20130225540 |
SUPPRESSION OF GLIAL FIBRILLARY ACIDIC PROTEIN
Provided herein are methods of decreasing glial fibrillary acidic protein (GFAP) levels in a cell. Such methods include administering an effective amount of a GFAP lowering compound to the cell.... |
|
|
US20130210024 |
COMBINATION TREATMENT OF CANCER
The present technology relates to a method of treating cancer by sensitizing human tumours to DNA damaging therapies through activating FBXO32 expression. Transactivation of FBXO32 through the... |
|
|
US20140256798 |
TALEN-BASED GENE CORRECTION
The invention is directed to transcription activator-like effector nuclease (TALEN)-mediated DNA editing of disease-causing mutations in the context of the human genome and human cells to treat... |
|
|
US20150158811 |
PHOTOREACTIVE SYNTHETIC REGULATOR OF PROTEIN FUNCTION AND METHODS OF USE THEREOF
The present disclosure provides a photoreactive synthetic regulator of protein function. The present disclosure further provides a light-regulated polypeptide that includes a subject synthetic... |
|
|
US20100305214 |
Use of a Monoterpene to Increase Tissue Repair
The invention relates to the use of a monoterpene to increase biological tissue repair, i.e. tissue regeneration or healing, the cosmetic use of a monoterpene to increase biological tissue repair... |
|
|
US20120039908 |
Control of Protein Glycosylation and Compositions and Methods Relating Thereto
The invention relates to novel methods for controlling the glycosylation of a protein and the protein produced thereby. An exemplary method of the invention comprises producing a protein... |
|
|
US20130096165 |
COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by... |
|
|
US20110172278 |
COMPOUNDS AND METHODS FOR MODULATING G PROTEIN-COUPLED RECEPTORS
The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by... |
|
|
US20140148402 |
Diagnostic Assays and Methods of Treating Pneumonia, Sepsis and Systemic Inflammatory Response Syndrome
Methods for assessing pneumonia in a patient, methods for managing treatment of a patient suspected of having pneumonia, and methods of managing treatment in a patient suffering from pneumonia.... |
|
|
US20120322147 |
DIRECT PROTEIN DELIVERY WITH ENGINEERED MICROVESICLES
The present invention relates to direct protein delivery with engineered micro vesicles. |
|
|
US20130164839 |
METHOD FOR CULTURING CELLS IN A SYSTEM COMPRISING LAMININ-5
The present invention is directed to providing a method for culturing cells in a system containing laminin-5. The method of the present invention is characterized by a culture system containing a... |
|
|
US20120184556 |
SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS
Disclosed are substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mGluR4 potentiators. |
|
|
US20120121589 |
MODIFIED EGFR ECTODOMAIN
A protein that attenuates EGFR and/or EGFR family members comprises a modified EGFR ectodomain. The protein inhibits signaling via the EGFR and/or EGFR family members. The protein includes a... |
|
|
US20090069439 |
Use of pargyline for the treatment of hair folliclies
Use of Pargyline for the production of a medicament for influencing the metabolism of hair follicles and the modulation of their vital cycle. |
|
|
US20120087862 |
ORGAN-SPECIFIC PROTEINS AND METHODS OF THEIR USE
The present invention relates generally to methods for identifying and using organ-specific proteins and transcripts. The present invention further provides compositions comprising organ-specific... |
|
|
US20130323220 |
TAL-Tet1 Fusion Proteins and Methods of Use Thereof
Fusion proteins comprising a DNA binding domain, e.g., a TAL effector repeat array or zinc finger, and a catalytic domain comprising a sequence that catalyzes hydroxylation of methylated cytosines... |
|
|
US20120122987 |
TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35)
Compounds are provided having agonistic activity against G protein-coupled receptor 35 (GPR35). The compounds are useful for providing antinociception, providing neuroprotection in case of stroke... |
|
|
US20140105829 |
THERAPEUTIC NANOEMULSION FORMULATION FOR THE TARGETED DELIVERY OF DOCETAXEL AND METHODS OF MAKING AND USING THE SAME
A novel nanoemulsion formulation useful for the delivery of docetaxel chemotherapeutic agents is provided, as well as methods of their preparation and use in cancer patients and for cancer imaging. |
|
|
US20110311442 |
DIRECT CELLULAR ENERGY DELIVERY SYSTEM
A lipid vesicle comprising a phospholipid which is a stable vesicle former and at least one unstable vesicle forming member, wherein the unstable vesicle forming member is selected from the group... |
|
|
US20130261167 |
ANCCA as a Diagnostic Biomarker and Therapeutic Target for Breast Cancers
The present invention provides methods of diagnosing breast cancer, confirming a diagnosis of breast cancer, predicting the survival of a breast cancer patient, and providing a therapeutic target... |
|
|
US20140080795 |
NRF2 Deficiency Influences Susceptibility to Steroid Resistance via HDAC2 Reduction
Methods for the treatment or prevention of diseases which are caused by the decreased concentrations of histone deacetylase 2 (HDAC2) in cells are described. The diseases which may be treated by... |
|
|
US20150159134 |
METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLS
The invention relates to a method for producing retinal pigment epithelial cells. |
|
|
US20130131154 |
Nonviral Gene Delivery Vector Iopamidol, Protamine, Ethiodized Oil Reagent (Viper)
Embodiments are related to nonviral gene delivery vectors using only FDA-approved components: iopamidol, protamine, and ethiodized oil. |
|
|
US20130034500 |
Cationic Steroid Antimicrobial Compositions and Methods of Use
The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a... |
|
|
US20100330086 |
CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE
The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a... |
|
|
US20140221301 |
COMBINATION TREATMENT FOR CANCER
A method of treating a cancer comprising administering to a subject in need thereof an effective amount of a glycylcycline, for example tigecycline in combination with a chemotherapeutic such as... |
|
|
US20120213738 |
Cardiac Repair By Reprogramming of Cardiac Fibroblasts Into Cardiomyocytes
The present invention involves the use of transcription factors including Tbx5, Mef2C, Hand2, myocardin and Gata4 to reprogram cardiac fibroblasts into cardiomyocytes, both in vitro and in vivo.... |